Healthcare-associated urinary tract infections in hospitalized urological patients-a global perspective: results from the GPIU studies 2003-2010

Basit Öğe Kaydı
dc.authoridbjerklund johansen, truls erik/0000-0003-3490-6460
dc.authoridtandogdu, zafer/0000-0002-5309-3656
dc.authorwosidNaber, Kurt/AAR-9997-2020
dc.contributor.authorCek, Mete
dc.contributor.authorTandogdu, Zafer
dc.contributor.authorWagenlehner, Florian
dc.contributor.authorTenke, Peter
dc.contributor.authorNaber, Kurt
dc.contributor.authorBjerklund-Johansen, Truls Erik
dc.date.accessioned2024-06-12T11:03:03Z
dc.date.available2024-06-12T11:03:03Z
dc.date.issued2014
dc.departmentTrakya Üniversitesien_US
dc.description.abstractEuropean Section for Infections in Urology has been conducting an annual prevalence survey investigating various aspects of healthcare-associated urinary tract infections (HAUTI) since 2003. The data on various clinical categories of HAUTI, the contamination status of HAUTI patients who underwent any urological intervention with regard to microorganisms isolated, resistance status and antibiotics used to treat HAUTI will be presented. Of a total of 19,756 patients screened, 1,866 patients had HAUTI (9.4 %); 1,313 males (70.4 %) and 553 (29.6 %) females. Mean age was 59.9 +/- A 18.2. Asymptomatic bacteriuria (ASB) and cystitis were the most frequent clinical diagnoses representing 27.0 and 26 % of all HAUTI, respectively. Echerichia coli was found to be the most frequent uropathogen (544 of 1,371 isolates) (39.7 %). Fluoroquinolones were preferred in 26.6 % of cases followed by cephalosporins (23.3 %), aminoglycosides (14.1 %) and penicillins (13.8 %). High global resistance rates to ciprofloxacin (> 50 %), cephalosporins (35-50 %) and penicillins (50 %) were found in the GPIU studies 2003-2010. We showed that around 10 % of hospitalized urological patients are at risk to develop HAUTI often caused by multiresistant uropathogens. Increased antibiotic use often with broad-spectrum antimicrobials will inevitably be followed by increasing bacterial resistance. To interrupt such a vicious cycle, our results suggest (1) there is still room for improvement in surgical prophylaxis in terms of limiting exposure to antibiotics and (2) far too many patients with ASB are being treated which shows that the new proposal of classification should be adopted where ABS is regarded as colonization and not as an infection to be treated.en_US
dc.identifier.doi10.1007/s00345-013-1218-9
dc.identifier.endpage1594en_US
dc.identifier.issn0724-4983
dc.identifier.issn1433-8726
dc.identifier.issue6en_US
dc.identifier.pmid24452449en_US
dc.identifier.startpage1587en_US
dc.identifier.urihttps://doi.org/10.1007/s00345-013-1218-9
dc.identifier.urihttps://hdl.handle.net/20.500.14551/21495
dc.identifier.volume32en_US
dc.identifier.wosWOS:000345336500029en_US
dc.identifier.wosqualityQ2en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherSpringeren_US
dc.relation.ispartofWorld Journal Of Urologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectHealthcare-Associated Infectionen_US
dc.subjectHealthcare-Associated Urinary Tract Infectionen_US
dc.subjectAntibioticsen_US
dc.subjectPrevalenceen_US
dc.subjectBacterial Resistanceen_US
dc.subjectNational Prevalence Surveyen_US
dc.subjectNosocomial Infectionsen_US
dc.subjectAntimicrobial Susceptibilityen_US
dc.subjectSurveillanceen_US
dc.subjectPathogensen_US
dc.subjectUsen_US
dc.subjectEpidemiologyen_US
dc.subjectMulticenteren_US
dc.subjectDepartmentsen_US
dc.titleHealthcare-associated urinary tract infections in hospitalized urological patients-a global perspective: results from the GPIU studies 2003-2010en_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu